Yüklüyor......

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Indian J Endocrinol Metab
Asıl Yazarlar: Kalra, Sanjay, Baruah, Manash P., Sahay, Rakesh K., Unnikrishnan, Ambika Gopalakrishnan, Uppal, Shweta, Adetunji, Omolara
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Medknow Publications & Media Pvt Ltd 2016
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4792029/
https://ncbi.nlm.nih.gov/pubmed/27042424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.176351
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!